Vanhees L, Defoor J G, Schepers D, Lijnen P, Peeters B Y, Lacante P H, Fagard R H
Department of Molecular and Cardiovascular Research, Faculty of Medicine, KU Leuven (University of Leuven), Belgium.
J Hypertens. 2000 Jan;18(1):35-43. doi: 10.1097/00004872-200018010-00006.
To compare the effects of a highly beta1-selective adrenoceptor antagonist bisoprolol with those of atenolol and placebo on endurance exercise capacity in young, healthy male volunteers.
Twelve subjects randomly received oral placebo, atenolol (100 mg/day) or bisoprolol (10 mg/day) for 3 weeks, following a double-blind cross-over design.
At the end of each period, the subjects performed an endurance exercise test on the bicycle ergometer at 70% of maximal aerobic power. Cardiac output was measured by means of an automated CO2-rebreathing method. Venous blood was sampled before, during and after exercise.
Exercise duration was not significantly different between the two drugs tested. Total exercise duration was significantly reduced by bisoprolol (-19.4 +/- 6.7%, P< 0.01) (mean +/- SEM) and by atenolol (-29.8 +/- 6.6%, P< 0.001), compared with placebo. Atenolol and bisoprolol were equally effective in lowering resting plasma renin activity, heart rate and systolic blood pressure. Resting and exercise stroke volume were significantly increased by both drugs, so that cardiac output was not significantly affected. Both drugs induced significant decreases in plasma-free fatty acid concentrations during recovery and blunted the exercise-induced increase. There were no significant relationships between the reduction of exercise duration and the haemodynamic changes or the degree of impairment of the exercise-induced increase in free fatty acid release resulting from beta-blockade.
It is concluded that both drugs affect endurance exercise capacity in young, normotensive men, with a tendency to a smaller reduction during bisoprolol treatment. Haemodynamic variables are unlikely to be involved in the reduction of endurance exercise capacity. The role of the reduced availability of plasma free fatty acids remains unclear.
比较高选择性β1肾上腺素能受体拮抗剂比索洛尔与阿替洛尔及安慰剂对年轻健康男性志愿者耐力运动能力的影响。
12名受试者按照双盲交叉设计,随机口服安慰剂、阿替洛尔(100毫克/天)或比索洛尔(10毫克/天),为期3周。
在每个阶段结束时,受试者在自行车测力计上以最大有氧功率的70%进行耐力运动测试。采用自动二氧化碳重呼吸法测量心输出量。在运动前、运动中和运动后采集静脉血样。
所测试的两种药物之间运动持续时间无显著差异。与安慰剂相比,比索洛尔(-19.4±6.7%,P<0.01)(均值±标准误)和阿替洛尔(-29.8±6.6%,P<0.001)均使总运动持续时间显著缩短。阿替洛尔和比索洛尔在降低静息血浆肾素活性、心率和收缩压方面同样有效。两种药物均使静息和运动时的每搏输出量显著增加,因此心输出量未受到显著影响。两种药物在恢复过程中均使血浆游离脂肪酸浓度显著降低,并减弱了运动诱导的升高。运动持续时间的缩短与血流动力学变化或β受体阻滞剂导致的运动诱导的游离脂肪酸释放增加受损程度之间无显著相关性。
得出结论,两种药物均影响年轻正常血压男性的耐力运动能力,比索洛尔治疗期间降低程度较小。血流动力学变量不太可能参与耐力运动能力的降低。血浆游离脂肪酸可用性降低的作用仍不清楚。